The ACSS2 Paradox: A Phosphorylation-Based Hypothesis

ACSS2 exhibits a tissue-specific duality: in peripheral cells, it promotes senescence by acetylating PAICS, enhancing autophagic degradation and inflammatory cGAS-STING signaling ACSS2 senescence role, while in neurons under AMPK activation or glucose starvation, it translocates to the nucleus to boost HAT activity and support resilience in aging and tauopathy models ACSS2 neuronal resilience. This paradox suggests a regulatory switch that determines ACSS2 localization and function, likely involving post-translational modifications. I propose that AMPK-mediated phosphorylation of ACSS2 at specific serine/threonine residues is the key determinant of its nuclear translocation in neurons, and that age-related decline in AMPK activity disrupts this switch, contributing to epigenetic dysregulation and neuronal aging.

Mechanistic Reasoning: A Phosphorylation-Driven Localization Switch

• AMPK Activation as a Trigger: Under glucose starvation or stress, AMPK is activated and phosphorylates ACSS2, promoting its nuclear import. This is supported by evidence that nuclear ACSS2 enhances HAT activity during nutrient depletion ACSS2 nuclear role. In neurons, this phosphorylation could occur at conserved sites analogous to those in other metabolic enzymes, such as the N-terminal domain, facilitating interaction with nuclear transport machinery.
• Aging-Induced AMPK Decline: With age, mitochondrial dysfunction and metabolic stress reduce AMPK activity metabolic-epigenetic cycle. This leads to hypophosphorylation of ACSS2, causing cytoplasmic retention. In neurons, this results in lower nuclear acetyl-CoA, reduced histone acetylation (e.g., H3K27ac), and impaired expression of neuroprotective genes. Simultaneously, cytoplasmic ACSS2 may acetylate PAICS, driving senescence-like pathways even in neurons, blurring the tissue-specific boundary.
• Interaction with PDC and Compartmentalization: PDC, which supports Gcn5-mediated H3K9 acetylation in yeast PDC role, might be co-regulated by AMPK. In neurons, AMPK could phosphorylate PDC to enhance its mitochondrial-nuclear shuttling, providing a complementary acetyl-CoA source. However, during aging, PDC inactivation via phosphorylation PDC inactivation could exacerbate nuclear acetyl-CoA deficits, creating a feedforward loop with ACSS2 mislocalization.

Testable Predictions and Falsifiability

This hypothesis generates specific, testable predictions:

1. AMPK-ACSS2 Physical Interaction: Co-immunoprecipitation and phospho-proteomics should reveal AMPK-dependent phosphorylation of ACSS2 in neurons under glucose starvation, but not in senescent fibroblasts. Mutating the phosphorylation site (e.g., serine to alanine) should block nuclear translocation.
2. Age-Related Changes in AMPK and ACSS2 Localization: In aged neuron models (e.g., iPSC-derived neurons from elderly donors), AMPK activity and nuclear ACSS2 levels should correlate positively. AMPK activators (e.g., AICAR) should rescue ACSS2 nuclear localization and histone acetylation marks like H3K27ac in aged neurons ACLY deficiency senescence.
3. Functional Outcomes: Knock-in of a phosphomimetic ACSS2 mutant (e.g., serine to aspartate) in aged neurons should enhance nuclear acetyl-CoA, reduce SASP factors, and improve synaptic gene expression. Conversely, AMPK inhibition should promote ACSS2 cytoplasmic retention and senescence markers in both neurons and peripheral cells.
4. Tissue-Specific Rescue: If the hypothesis holds, AMPK activation in peripheral tissues might paradoxically enhance senescence by promoting ACSS2 nuclear translocation, but this could be context-dependent. Testing in vivo with tissue-specific AMPK knockout models would clarify.

Broader Implications

This phosphorylation switch framework resolves the ACSS2 paradox by emphasizing dynamic regulation over static tissue differences. It suggests that therapeutic strategies should target AMPK activation specifically in neurons to harness ACSS2's pro-resilience function, while avoiding off-target effects in peripheral tissues. Moreover, it links AMPK, ACSS2, and PDC into a coordinated network that declines with age, offering multiple points for intervention—such as combining AMPK activators with acetate supplementation to boost nuclear acetyl-CoA acetate rejuvenation. If falsified, the hypothesis would redirect focus to other regulators, such as acetyl-CoA synthetase interacting proteins or non-canonical acetylation pathways, but its testable nature ensures rapid progress in understanding the metabolic-epigenetic axis of aging.